Top Ad unit 728 × 90

Radiology News


Intracranial Gadolinium Deposition-From the Journals

  • Gadolinium-based contrast agents (GBCAs) represent a family of aminopolycarboxylic acid ligands chelated to gadolinium, a rare earth metal capable of altering the relaxivity of nearby water molecules by means of interaction with its unpaired electrons.
  • As free gadolinium is cytotoxic, the presence of the organic ligand serves as a physiologic chaperone, allowing an otherwise toxic metal to be safely administered intravenously and excreted.
  • Despite relatively uncomplicated initial clinical trials in the early 1990s, a 2006 study causally associated the administration of gadolinium with the development of nephrogenic systemic fibrosis in patients with pre-existing renal dysfunction. 
  • An article published in Radiology in 2015  showed Elemental gadolinium accumulates in neuronal tissues after intravenous administration of gadolinium-based contrast agents (GBCAs), even in patients with normal renal and hepatobiliary function.
  • The clinical significance of these findings is incompletely understood at this time.

Robert J. McDonaldJennifer S. McDonaldDavid F. KallmesMark E. JentoftDavid L. MurrayKent R. ThielenEric E. Williamson, and Laurence J. Eckel
Radiology 2015 275:3772-782 

Intracranial Gadolinium Deposition-From the Journals Reviewed by Sumer Sethi on Thursday, April 07, 2016 Rating: 5

No comments:

All Rights Reserved by Sumer's Radiology Blog © 2014 - 2015
Powered By Blogger,

Contact Form


Email *

Message *

All contents copyrights with Sumer Sethi. Powered by Blogger.